Get the Stockscreener App
7.70
1.03%
-0.08
After Hours:
7.70
Personalis Inc stock is traded at $7.70, with a volume of 1.28M.
It is down -1.03% in the last 24 hours and down -7.34% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$7.78
Open:
$7.93
24h Volume:
1.28M
Relative Volume:
0.90
Market Cap:
$805.67M
Revenue:
$69.65M
Net Income/Loss:
$-81.27M
P/E Ratio:
-8.4727
EPS:
-0.9088
Net Cash Flow:
$-79.45M
1W Performance:
+10.63%
1M Performance:
-7.34%
6M Performance:
+28.76%
1Y Performance:
+113.89%
1-Day Range:
$7.69
$8.23
1-Week Range:
$6.65
$8.23
52-Week Range:
$2.8262
$11.50
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
7.70 | 814.04M | 69.65M | -81.27M | -79.45M | -0.9088 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Sell Signal: Can Personalis Inc deliver consistent EPS growthOil Prices & Weekly Setup with High ROI Potential - baoquankhu1.vn
Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 - Insider Monkey
10 best diagnostics and research stocks to buy according to analysts - MSN
PSNL SEC FilingsPersonalis 10-K, 10-Q, 8-K Forms - Stock Titan
Personalis, Inc. (PSNL): A bull case theory - MSN
Personalis appoints Richard Chen as president and updates compensation package - Investing.com Australia
229,435 Shares in Personalis, Inc. $PSNL Bought by Oracle Investment Management Inc. - MarketBeat
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption - BioSpace
Personalis promotes Richard Chen to president role By Investing.com - Investing.com South Africa
Personalis appoints Richard Chen as president and updates compensation package By Investing.com - Investing.com India
Personalis (PSNL) Appoints Richard Chen as President - GuruFocus
Personalis (PSNL) CFO granted 206,250 options and 34,375 RSUs - Stock Titan
Personalis (PSNL) grants options and RSUs to Chief Legal Officer - Stock Titan
Personalis (PSNL) CEO receives major stock option and RSU grants - Stock Titan
Personalis (PSNL) awards RSUs and stock options to its CMO - Stock Titan
Investor Mood: Can Personalis Inc grow without external funding2026 Chart Watch & Expert Approved Trade Ideas - baoquankhu1.vn
Personalis promotes Richard Chen to president role - Investing.com
Personalis (NASDAQ: PSNL) elevates Richard Chen to President - Stock Titan
Personalis, Inc. Announces the Promotion of Richard Chen, M.D., M.S., to the Position of President - marketscreener.com
Aug Movers: Should you avoid Personalis Inc stock right now2026 Price Momentum & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Personalis Q2 2025 Earnings Preview - MSN
Personalis (NASDAQ:PSNL) Trading 6.6% HigherTime to Buy? - MarketBeat
Personalis (NASDAQ:PSNL) Stock Price Down 8.1%What's Next? - MarketBeat
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal - BioSpace
Personalis (PSNL) Publishes Promising Study on Cancer Detection Method - GuruFocus
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal® - Business Wire
Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Growth Report: Is Personalis Inc showing insider buyingEarnings Growth Report & Consistent Profit Trade Alerts - baoquankhu1.vn
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? - MSN
Personalis (NASDAQ:PSNL) Rating Increased to Hold at Wall Street Zen - MarketBeat
Momentum Shift: Is Personalis Inc benefiting from interest rate changesJuly 2025 Earnings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Is Personalis Inc. stock attractive after correctionTrade Risk Summary & Weekly High Momentum Picks - Naître et grandir
Personalis Stock Pre-Market (-5.3%): FY26 Guidance Overshadows Q4 EPS Beat - Trefis
Morgan Stanley Has Lowered Expectations for Personalis (NASDAQ:PSNL) Stock Price - MarketBeat
PSNL: Morgan Stanley Maintains Equal-Weight, Lowers Price Target - GuruFocus
Personalis, Inc. $PSNL Stake Boosted by ARK Investment Management LLC - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Short Interest Up 21.2% in February - MarketBeat
Personalis Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Personalis (NASDAQ:PSNL) Shares Gap DownTime to Sell? - MarketBeat
Will Personalis Inc. outperform small cap indexesBear Alert & Free Verified High Yield Trade Plans - mfd.ru
Breaking Down Personalis: 5 Analysts Share Their Views - Sahm
Personalis, Inc. (NASDAQ:PSNL) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcellx Inc (ACLX), DENTSPLY SIRONA (XRAY) and Personalis (PSNL) - The Globe and Mail
Personalis (NASDAQ:PSNL) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Personalis 2025 Financial Results: Revenue, Loss, and 2026 ForecastNews and Statistics - IndexBox
Personalis, Inc. (PSNL) Stock Analysis: Exploring a Promising 24.98% Upside with Innovative Cancer Genomics - DirectorsTalk Interviews
Personalis (NASDAQ:PSNL) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Personalis, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham raises Personalis stock price target on reimbursement wins By Investing.com - Investing.com Nigeria
Needham raises Personalis stock price target on reimbursement wins - Investing.com Australia
PSNL Stock Sees Price Target Increase by Needham | PSNL Stock Ne - GuruFocus
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):